SEC Filing Summary for Alnylam Pharmaceuticals, Inc.

Bryan Supran, EVP, CLO and Secretary of Alnylam Pharmaceuticals, Inc., reported a disposition of 1,758 shares of Common Stock on October 2, 2026. The shares were sold at a price of $226.88 per share, resulting in a post-transaction ownership of 12,807 shares. The sale was executed automatically by the Company to cover mandatory tax withholding obligations upon the vesting and settlement of restricted stock units, as per footnote F1.